Mizuho Securities analyst Uy Ear maintains $Alkermes (ALKS.US)$ with a buy rating, and sets the target price at $40.
According to TipRanks data, the analyst has a success rate of 41.9% and a total average return of 3.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
The adjustment in valuation multiple for Alkermes, influenced by the recent trend among biotech peers, is the basis for the revised outlook. The upcoming expert discussion on sleep disorders, particularly anticipating orexin data in 2025, will concentrate on the projected updates from Alkermes and Centessa's Phase 2 narcolepsy data.
The firm adjusted its forecast following a sum-of-the-parts analysis. The discussion among investors is increasingly focusing on ALKS 2680, anticipating more spotlight as it heads towards Phase 2 outcomes in the latter half of 2025. Its potential impact on the $10B branded narcolepsy and idiopathic hypersomnia markets is being closely watched.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞穗证券分析师Uy Ear维持$阿尔凯默斯 (ALKS.US)$买入评级，目标价40美元。
根据TipRanks数据显示，该分析师近一年总胜率为41.9%，总平均回报率为3.3%。
此外，综合报道，$阿尔凯默斯 (ALKS.US)$近期主要分析师观点如下：
受生物技术同行最近趋势的影响，Alkermes估值倍数的调整是修订前景的基础。即将举行的关于睡眠障碍的专家讨论，特别是对2025年食欲素数据的预测，将集中在Alkermes和Centessa的第二阶段发作性睡病数据的预计更新上。
该公司在进行各部分总和分析后调整了预测。投资者之间的讨论越来越多地集中在ALKS 2680上，预计随着ALKS 2680在2025年下半年迈向第二阶段的结果，他们将受到更多关注。它对价值100亿美元的品牌发作性睡病和特发性睡眠过度市场的潜在影响正在受到密切关注。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
